Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome
- PMID: 20201749
- DOI: 10.3109/00365591003667351
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome
Abstract
Objective: In this prospective study, the effects of an angiotensin-converting enzyme inhibitor [lisinopril (LIS)] and an angiotensin II receptor antagonist [losartan (LOS)] were compared in nephrotic patients with idiopathic membranous nephropathy.
Material and methods: Twenty-seven patients (13 males, mean age +/- SD 51.3 +/- 15.4 years) were treated with LIS (13 patients, six males, mean age 52.1 +/- 15.3 years) or LOS (14 patients, seven males, mean age 50.5 +/- 15.5 years) for 12 months. At baseline and after the treatment period, serum albumin, total cholesterol, estimated glomerular filtration rate (GFR), 24 h proteinuria and mean arterial pressure were determined.
Results: Proteinuria (g/24 h) was significantly reduced in both groups (LIS from 4.82 +/- 1.26 to 1.75 +/- 0.64, p < 0.0001; LOS from 4.55 +/- 1.09 to 2.54 +/- 1.94, p = 0.002) (all results +/- SD). Serum albumin levels (g/dl) increased significantly in both groups (LIS 2.27 +/- 0.41 to 3.17 +/- 0.63, p < 0.0001; LOS 2.93 +/- 0.40 to 3.55 +/- 0.44, p < 0.0001). GFR (ml/min x 1.73 m(2)) did not change significantly in either group (LIS 55 +/- 17 to 56 +/- 17, p = 0.65; LOS 64 +/- 18 to 59 +/- 16, p = 0.13). Total cholesterol (mg/dl) was significantly reduced only in the lisinopril group (LIS 347 +/- 81 to 266 +/- 64, p < 0.0001; LOS 306 +/- 58 to 263 +/- 77, p = 0.138). Mean arterial pressure (mmHg) was reduced in both groups (LIS 107 +/- 12 to 95 +/- 6, p < 0.0001; LOS 104 +/- 10 to 96 +/- 5, p = 0.003). In the comparison between the two groups, serum albumin levels were higher in the losartan group at baseline (p < 0.0001) and after 12 months (p = 0.029). There were no significant differences between the baseline and end-of-study values for the rest of the studied parameters.
Conclusion: Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure.
Similar articles
-
Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy.Ren Fail. 2010 Jun;32(5):566-71. doi: 10.3109/08860221003728754. Ren Fail. 2010. PMID: 20486839 Clinical Trial.
-
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.Am J Kidney Dis. 2000 Mar;35(3):381-91. doi: 10.1016/s0272-6386(00)70190-9. Am J Kidney Dis. 2000. PMID: 10692263 Clinical Trial.
-
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Arch Intern Med. 2005 Apr 25;165(8):936-46. doi: 10.1001/archinte.165.8.936. Arch Intern Med. 2005. PMID: 15851647 Clinical Trial.
-
Membranous nephropathy in children: clinical presentation and therapeutic approach.Pediatr Nephrol. 2010 Aug;25(8):1419-28. doi: 10.1007/s00467-009-1324-5. Epub 2009 Nov 12. Pediatr Nephrol. 2010. PMID: 19908069 Free PMC article. Review.
-
New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.Autoimmun Rev. 2016 Jun;15(6):529-38. doi: 10.1016/j.autrev.2016.02.014. Epub 2016 Feb 11. Autoimmun Rev. 2016. PMID: 26876383 Review.
Cited by
-
Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis.PeerJ. 2020 Mar 12;8:e8575. doi: 10.7717/peerj.8575. eCollection 2020. PeerJ. 2020. PMID: 32201639 Free PMC article.
-
Treatment of membranous nephropathy: time for a paradigm shift.Nat Rev Nephrol. 2017 Sep;13(9):563-579. doi: 10.1038/nrneph.2017.92. Epub 2017 Jul 3. Nat Rev Nephrol. 2017. PMID: 28669992 Review.
-
Chapter 7: Idiopathic membranous nephropathy.Kidney Int Suppl (2011). 2012 Jun;2(2):186-197. doi: 10.1038/kisup.2012.20. Kidney Int Suppl (2011). 2012. PMID: 25018932 Free PMC article. No abstract available.
-
Case Report: A Rare Presentation of NSAID-Induced Secondary Membranous Nephropathy in a Pediatric Patient.Front Pediatr. 2021 Apr 23;9:670575. doi: 10.3389/fped.2021.670575. eCollection 2021. Front Pediatr. 2021. PMID: 33968861 Free PMC article.